NCT05549921View on ClinicalTrials.gov

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
Soft Tissue Sarcoma
Interventions
BIOLOGICAL

NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

Trial Locations (2)

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

Unknown

RECRUITING

Sun Yat-Sen Univerisity Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Guangdong Xiangxue Precision Medical Technology Co., Ltd.

INDUSTRY

lead

Sun Yat-sen University

OTHER